Yes, totally agree with you on this. The possibility for achieving the first two milestones (a) and (b) is very high, probably over 90%, and we will receive the payment of $0.90/share (almost 400% gain from the original $0.17 investment) by the end of 2018 or early 2019 after the enrollment of the very first patient in the clinical trial (see the text from the SEC filing attached below). The rest of the payment ($1.90/share) is simply a bonus, and I don't really care much about it; if we can receive it that would be awesome! Otherwise, I'm very happy with the 400% gain from the first two milestones.
Also, given the very low amount of breakup-fee $1.68M, there is the possibility of receiving counter higher bids in the upcoming weeks.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.